Podium Presentations
Monday, 7 September 2015
16:15 - 17:15
RESEARCH PODIUM PRESENTATIONS - SESSION I

16:15 - 17:15
Room: Gran Salón del Parque 1
CA: CANCER OUTCOMES RESEARCH STUDIES
CA1, CA3, CA4 presented in Spanish; CA2 presented in Portuguese

CA1

16:15 - 16:30

ASOCIACIÓN SIGNIFICATIVA ENTRE LA ENFERMEDAD VOLUMINOSA CERCANA A CRANEO Y NEUROEJE Y LA INFILTRACIÓN SECUNDARIA A SISTEMA NERVIOSO CENTRAL EN PACIENTES CON LINFOMA DIFUSO DE CÉLULAS GRANDES B

Huerta-Guzman J1, Ignacio-Ibarra G1, Talavera-Piña J1, Sierra-Ramírez J2, Contreras-Hernandez I1
1Instituto Mexicano del Seguro Social, Mexico, D.F., Mexico, 2Instituto Politecnico Nacional, Mexico, D.F., Mexico

CA2

16:30 - 16:45

ACCESS TO THE PROCEDURE CARE OF COLORECTAL CANCER IN BRAZILIAN PUBLIC HEALTH SYSTEM: USE OF DIAGNOSIS RESOURCES IN SÃO PAULO STATE

Oliveira D1, Luque A1, Junqueira Junior SM1, Oliveira FM1, Cabra HA2
1Johnson & Johnson Medical Brazil, São Paulo, Brazil, 2Johnson & Johnson Medical, México, D.F., Mexico

CA3

16:45 - 17:00

PROFILE OF COLORECTAL CANCER TREATMENT WITHIN THE BRAZILIAN PUBLIC SETTING: ANALYSIS OF DATASUS AQ DATABASE

Fabre Ballalai Ferraz A1, Rosim R1, Anaya P2
1IMS Health, São Paulo, Brazil, 2IMS Health, México, D.F., Mexico

CA4

17:00 - 17:15

COSTO DE CÁNCER DE COLON AVANZADO EN LOS ESTABLECIMIENTOS HOSPITALARIOS DEL PERÚ

Gutierrez-Aguado A1, Escobedo-Palza S2, Timana-Ruiz R3, Sobrevilla-Ricci A4, Mosqueira-Lovón R4
1UNMSM, Lima, Peru, 2SPEAS, Lima, Peru, 3SOMPEGS, Lima, Peru, 4Abt Associates-HFG Peru, Lima, Peru

16:15 - 17:15
Room: Las Araucarias 2
CE: COST-EFFECTIVENESS STUDIES
CE1 presented in Portuguese; CE2, CE3, CE4 presented in Spanish

CE1

16:15 - 16:30

COST-EFFECTIVENESS ANALYSIS FOR CERVICAL CANCER SCREENING USING HPV TESTS IN CHILE

Franco Figueira S1, Cachoeira CV1, Souza FH1, Kano BY1, Silva M2, Poulios N3
1Roche Diagnostics LATAM, São Paulo, Brazil, 2Roche Diagnostics Chile, Santiago, Chile, 3Roche Molecular Systems, Inc., Pleasanton, CA, USA

CE2

16:30 - 16:45

EVALUACIÓN DEL COSTO-EFECTIVIDAD Y COSTO-UTILIDAD DEL USO DE RIVAROXABÁN EN PACIENTES CON FIBRILACIÓN AURICULAR NO VALVULAR FRENTE A WARFARINA EN EL CONTEXTO ECUATORIANO

Romero M, Alfonso Quiñones PA, Acero G, Marrugo R
Salutia Foundation, Bogotá, Colombia

CE3

16:45 - 17:00

PROJECTED ECONOMIC IMPACT OF INCREASED USE OF BIOLOGIC TREATMENTS FOR RHEUMATOID ARTHRITIS IN ARGENTINA, COLOMBIA, AND MEXICO OVER 10 YEARS

Rojas Serrano J1, de Abreu MM2, Tundia N3, Skup M3, Sorg R4, Macaulay D4, Bao Y3, Chaves L3, Chao J3
1National Autonomous University of Mexico, México, D.F., Mexico, 2Federal University of Rio de Janeiro, Rio de Janeiro, Brazil, 3AbbVie Inc., North Chicago, IL, USA, 4Analysis Group, Inc., New York, NY, USA

CE4

17:00 - 17:15

EVALUACIÓN COSTO-UTILIDAD DE DOS ALTERNATIVAS DE VACUNACIÓN PARA EL VIRUS DEL PAPILOMA HUMANO (VPH) EN LA PREVENCIÓN DEL CANCER CERVICAL UTERINO

Tejada RA, Bolaños-Díaz R, Beltrán J, Roman Y
Instituto Nacional de Salud, Lima, Peru

16:15 - 17:15
Room: Gran Salón del Parque 3
IN: INFECTIOUS DISEASE STUDIES
IN1, IN2, IN4 presented in Spanish; IN3 presented in English

IN1

16:15 - 16:30

ANÁLISIS DE COSTO-UTILIDAD DE PCV13 VERSUS PPSV23 EN ADULTOS DE 65 AÑOS Y MÁS

Biagini Leandro L1, Rojas Rubén R1, Fuentealba Francisca F1, Pezzani Marcela M2
1Universidad Mayor, Santiago, Chile, 2Universidad San Sebastián, Santiago, Chile

IN2

16:30 - 16:45

METHODOLOGICAL CHANGES IN BURDEN OF INFECTIOUS DISEASE ESTIMATION: THE CASE OF PNEUMOCOCCAL INFECTION IN COLOMBIA

Lasalvia P1, Castañeda-Cardona C1, Rosselli D2
1Pontificia Universidad Javeriana, Bogota, Colombia, 2Pontifícia Universidade Javeriana, Bogotá, Colombia

IN3

16:45 - 17:00

ESTIMATING THE SUPPLY AND DEMAND OF BUTANTAN DENGUE VACCINE IN BRAZIL

Garcia CR1, Wilson-Barthes M1, Coelho GE2, Domingues C2, Constenla DO1
1Johns Hopkins University, Baltimore, MD, USA, 2Ministério da Saúde, Brasilia, Brazil

IN4

17:00 - 17:15

ECONOMIC COSTS OF BACTERIAL MENINGITIS: A SYSTEMATIC REVIEW

Alvis-Zakzuk N1, Carrasquilla-Sotomayor M2, Alvis-Guzmán N2, Paternina-Caicedo A2, Herrera-Arrieta J3, Coronel-Rodríguez W2, Castillo-Saavedra D4
1Instituto Nacional de Salud, Bogotá, Colombia, 2Universidad de Cartagena, Centro de Investigación y Docencia, Hospital Infantil Napoleón Franco Pareja, Cartagena de Indias, Colombia, 3Universidad del Sinu, Cartagena, Colombia, 4Funinderma. Grupo de Investigación en Economía de la Salud, Bogotá, Colombia

16:15 - 17:15
Room: Las Araucarias 1
MD: MEDICAL DEVICE & DIAGNOSTIC RESEARCH STUDIES
MD1, MD2, MD4 presented in Spanish; MD3 presented in Portuguese

MD1

16:15 - 16:30

EVALUACIÓN ECONÓMICA DEL CARDIO-DESFIBRILADOR IMPLANTABLE COMPARADO CON LA TERAPIA FARMACOLÓGICA OPTIMA PARA EL TRATAMIENTO DE LOS PACIENTES CON FALLA CARDIACA EN COLOMBIA

Atehortua SC1, Castro P1, Ceballos M2, Senior JM1, Saldarriaga C1, Giraldo N1
1Universidad de Antioquia, Medellín, Colombia, 2Instituto de Evaluación Tecnológica en Salud (IETS), Bogotá, Colombia

MD2

16:30 - 16:45

MEDICAL DEVICES – FROM LICENSING TO COVERAGE: HIGHLIGHTS FROM ARGENTINA, BRAZIL, COLOMBIA, AND MEXICO

Rey-Ares L1, Garay U1, García-Martí S1, Gilardino R2, Cabra HA3, Pichón-Riviere A4, Augustovski F1
1Institute for Clinical Effectiveness and Health Policy (IECS), Buenos Aires, Argentina, 2Johnson & Johnson Medical Argentina, Buenos Aires, Argentina, 3Johnson & Johnson Medical, México, D.F., Mexico, 4y Director del Centro Colaborador de la OMS/OPS en ETS, Buenos Aires, Argentina

MD3

16:45 - 17:00

STAPLED HAEMORRHOIDOPEXY TO TREAT HEMORRHOIDS GRADE III AND IV: A SYSTEMATIC REVIEW AND META-ANALYSIS

Luque A1, Junqueira Junior SM1, Oliveira FM1, Oliveira D1, Cabra HA2
1Johnson & Johnson Medical Brazil, São Paulo, Brazil, 2Johnson & Johnson Medical, México, D.F., Mexico

MD4

17:00 - 17:15

COST EFFECTIVENESS OF DRUG COATED BALLOON VERSUS PERCUTANEOUS TRANSLUMINAL BALLOON ANGIOPLASTY IN THE TREATMENT OF PERIPHERAL ARTERIAL DISEASE IN LOWER LIMBS IN BRAZIL

Pepe C1, Fahham L2, Follador W3, Valencia J4, Orozco JJ5
1Grupo Resulta, São Paulo, Brazil, 2Sense Company, São Paulo, Brazil, 3Medtronic, São Paulo, Brazil, 4Medtronic, Miami, FL, USA, 5Medtronic, Medellin, Colombia

16:15 - 17:15
Room: Gran Salón del Parque 2
PR: PRICING AND HEALTH SYSTEM STUDIES
PR1 and PR2 presented in Spanish; PR3 presented in Portuguese; PR4 presented in English with simultaneous English/Spanish/Portuguese interpretation

PR2

16:15 - 16:30

COMPETITION AND STRATEGIC REGULATION IN THE ARGENTINE PHARMACEUTICAL MARKET: A COMPARATIVE STUDY OF SIX THERAPEUTIC CLASSES

Maceira D, Palacios A
Center for the Study of State and Society (CEDES), Buenos Aires, Argentina

PR3

16:30 - 16:45

POTENTIAL PUBLIC RESOURCE SAVINGS IN BRAZIL: THE SOMATROPIN CASE

Lemos LL1, Silva MR1, Santos JB2, Costa Jd1, Gomes RM1, Nascimento RC2, Almeida AM3, Guerra Júnior AA2
1CCATES, Federal University of Minas Gerais, Belo Horizonte, Brazil, 2College of Pharmacy, Federal University of Minas Gerais, Belo Horizonte, Brazil, 3College of Medical Sciences of Minas Gerais, Belo Horizonte, Brazil

PR4

16:45 - 17:00

IMPACT OF MAJOR CHANGES TO THE BRAZILIAN HEALTH CARE SYSTEM UTILIZING THE HEAT MAPS PROJECT

Panish JM1, Junqueira Junior SM2, Cabra HA3, Hutzul T4, Hensen M5
1Ethicon, Somerville, NJ, USA, 2Johnson & Johnson Medical Brazil, São Paulo, Brazil, 3Johnson & Johnson Medical, México, D.F., Mexico, 4Johnson & Johnson Medical Products, Markham, ON, Canada, 5Pharmerit BV, Rotterdam, The Netherlands
17:30 - 18:30
RESEARCH PODIUM PRESENTATIONS - SESSION II

17:30 - 18:30
Room: Gran Salón del Parque 1
BI: BUDGET IMPACT AND COST STUDIES
BI1 presented in Spanish; BI2, BI3, BI4 presented in English

BI1

17:30 - 17:45

COST REDUCTION FOR A HEALTH SYSTEM THROUGH DECREASING NUMBER OF ELIGIBLE PATIENTS FOR BIOLOGICAL THERAPY IN PATIENTS WITH RHEUMATOID ARTHRITIS USING THE TREAT TO TARGET RECOMMENDATIONS

Santos-Moreno P, Saavedra-Martínez G, Bello-Gualtero J, Gómez-Mora D
Biomab, Centro de Artritis Reumatoide, Bogota, Colombia

BI2

17:45 - 18:00

TREATMENT PATTERNS AND BUDGETARY IMPACT OF CHEMOTHERAPY DRUGS IN A BRAZILIAN PRIVATE HEALTH PLAN (PHP)

Nishikawa AM1, Castro AP1, Alves AF1, Medina P1, Clark LG2
1Evidências - Kantar Health, Campinas, Brazil, 2Evidências - Kantar Health, São Paulo, Brazil

BI3

18:00 - 18:15

FINANCIAL IMPACT OF HOSPITAL EXPENDITURE IN CHRONIC DISEASES FOR SEGURO POPULAR

Rodríguez-Aguilar R, Gutiérrez-Delgado C
Economic Analysis Unit, Mexico City, Mexico

BI4

18:15 - 18:30

HOSPITALIZATION COSTS OF TYPE 2 DIABETES MELLITUS (T2DM) PATIENTS IN A PUBLIC HOSPITAL IN BRAZIL

Saad R1, Piedade A2, Wiens A1, Baptista DR1, Pontarolo R1
1Universidade Federal do Paraná, Curitiba, Brazil, 2Evidências - Kantar Health, Campinas, Brazil

17:30 - 18:30
Room: Las Araucarias 1
CV: CARDIOVASCULAR DISEASE & DIABETES RESEARCH STUDIES
CV1, CV2, CV3 presented in Spanish; CV4 presented in English

CV1

17:30 - 17:45

ASSOCIATION OF ADHERENCE STATUS AS MEASURED USING TWO SINGLE-ITEM PHYSICIAN-ADMINISTERED METHODS WITH CARDIOVASCULAR RISK IN PATIENTS TAKING ANTIHYPERTENSIVE MEDICATION

Rivera O1, Morales F2, Cordova P2, Fernández P2, López M2, MacDonald K3, Levengood M4, Vancayzeele S5, Aerts A5, Denhaerynck K3, Abraham I4, Villa L2
1Universidad de Concepción, Concepción, Chile, 2Facultad de Farmacia, Universidad de Concepción, Concepción, Chile, 3Matrix 45, Tucson, AZ, USA, 4The University of Arizona, Tucson, AZ, USA, 5N.V. Novartis Pharma S.A., Vilvoorde, Belgium

CV2

17:45 - 18:00

APIXABAN IN PATIENTS WITH ATRIAL FIBRILLATION: PATIENT CHARACTERISTICS OF THE LATIN AMERICA COHORT FROM A MULTINATIONAL CLINICAL TRIAL

Avezum A1, Bahit MC2, Hermosillo JA3, Zanetti FL4, Perafan P5, Juarez-Garcia A6, Vulcano C7, Cubillos LA8, Korenblat Donato BM9
1Dante Pazzanese Institute of Cardiology, São Paulo, Brazil, 2INECO Neurociencias, Rosario, Argentina, 3Insto Nacional de Cardiología, México, DF, Mexico, 4Universidad de La Frontera, Temuco, Chile, 5Fundación Valle del Lili, Cali, Colombia, 6Bristol-Myers Squibb Company, México, DF, Mexico, 7Bristol-Myers Squibb, Buenos Aires, Argentina, 8Pfizer, New Jersey, NJ, USA, 9Bristol-Myers Squibb, Wallingford, CT, USA

CV3

18:00 - 18:15

ARETAEUS: RETROSPECTIVE STUDY OF MEDICATION USAGE PATTERNS FOLLOWING THE DIAGNOSIS OF TYPE 2 DIABETES IN LATIN AMERICA

Gagliardino JJ1, Granell RA2, Eliaschewitz FG3, Iglay K4, Brodovicz K4, Yu S4, González CD4, Shankar R4, Heisel O5, Bloomfield S5, Keown P5, Tunceli K6
1Centro de Endocrinología Experimental y Aplicada (UNLP-CONICET La Plata), Buenos Aires, Argentina, 2Instituto Mexicano del Seguro Social, Guadalajara, Mexico, 3CPClin Clinical Research Center, São Paulo, Brazil, 4Merck & Co., Inc., Kenilworth, NJ, USA, 5Syreon Corporation, Vancouver, BC, Canada, 6Merck & Co., Inc., North Wales, PA, USA

CV4

18:15 - 18:30

ECONOMICS OF DIABETES MELLITUS: THEORY AND EVIDENCE FOR BRAZILIAN DATA IN 2008

Balbinotto G, Wiest R, Jacinto P
Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil

17:30 - 18:30
Room: Gran Salón del Parque 3
HT: HEALTH TECHNOLOGY ASSESSMENT STUDIES
HT1, HT3, HT4 presented in Spanish; HT2 presented in English

HT1

17:30 - 17:45

RAPID INCREASE OF HEALTH LITIGATION AS A MEANS OF MARKET ACCESS FOR INNOVATIVE MEDICINES IN COLOMBIA AND THE POTENTIAL ROLE OF HEALTH TECHNOLOGY ASSESSMENT

Leon Kershaw A, Izmirlieva M
IHS, London, UK

HT2

17:45 - 18:00

FROM LAW TO REALITY: MEASURING TIME-TO-ACCESS OF CONITEC APPROVED DRUGS IN BRAZILIAN PUBLIC HEALTH CARE SYSTEM (SUS) IN THE STATE OF PARANÁ

Piedade AD1, Henriques RS2
1Evidências - Kantar Health, Campinas, Brazil, 2Universidade Federal do Paraná, Curitiba, Brazil

HT4

18:00 - 18:15

PROCESO DE INCORPORACIÓN DE FÁRMACOS A LA LISTA POSITIVA DE MEDICAMENTOS (LPM) PARA LOS PRESTADORES INTEGRALES DE SALUD: EXPERIENCIA EN EL MINISTERIO DE SALUD PÚBLICA (MSP) DE URUGUAY

Croci A, Deminco A, Villamil E, Alemán A, Pérez Galán A
Ministry of Public Health, Montevideo, Uruguay

17:30 - 18:30
Room: Gran Salón del Parque 2
PP: PATIENT AND CLINICIAN PREFERENCES & QALY STUDIES
PP1 and PP3 presented in Portuguese; PP2 presented in Spanish; PP4 presented in English with simultaneous English/Spanish/Portuguese interpretation

PP1

17:30 - 17:45

BARRIERS TO PARTICIPATION IN TRIALS OF CANCER: A SURVEY ON CLINICAL RESEARCH PERCEPTION

Holtz L1, Cecilio L1, Julian G2, Minowa E3
1Oncoguia, São Paulo, Brazil, 2Evidências - Kantar Health, São Paulo, Brazil, 3Evidências - Kantar Health, Campinas, Brazil

PP2

17:45 - 18:00

AN EQ-5D-5L VALUE SET BASED ON URUGUAYAN POPULATION PREFERENCES: REPORT OF THE FIRST EXPERIENCE IN LATIN AMERICA

Augustovski F1, Rey-Ares L1, Irazola V1, Garay U1, Gianneo O2, Fernandez G2, Morales MR2, Gibbons L1, Ramos-Goñi JM3
1Institute for Clinical Effectiveness and Health Policy (IECS), Buenos Aires, Argentina, 2Fondo Nacional de Recursos, Montevideo, Uruguay, 3The EuroQol Group Foundation, Rotterdam, The Netherlands

PP3

18:00 - 18:15

COST-EFFECTIVENESS ANALYSIS FOR CERVICAL CANCER SCREENING USING HPV TESTS IN BRAZIL

Franco Figueira S1, Cachoeira CV1, Petry Hasegawa AC2, Kano BY1, Souza FH1, Poulios N3
1Roche Diagnostics LATAM, São Paulo, Brazil, 2Roche Diagnostics Brazil, São Paulo, Brazil, 3Roche Molecular Systems, Inc., Pleasanton, CA, USA

PP4

18:15 - 18:30

AN UNDEVELOPED PICTURE: THE AVAILABILITY OF UTILITY VALUATIONS IN LATIN AMERICA – HOW WILL THEY AFFECT QALYS?

Montgomery S1, Stewart G2, Kusel J1
1Costello Medical Consulting Ltd, Cambridge, UK, 2Costello Medical Consulting Ltd., Cambridge, UK

17:30 - 18:30
Room: Las Araucarias 2
RM: RESEARCH ON METHODS STUDIES
Presented in Spanish

RM1

17:30 - 17:45

STANDARDIZATION PROCESS OF RAW DATASUS AND CONSUMPTION ANALYSIS OF ONCOLOGY THERAPIES IN THE BRAZIL PUBLIC HEALTH CARE SYSTEM: A COMPARISON BETWEEN RAW AND STANDARDIZED DATASET IN COLORECTAL AND LUNG CANCER

Fabre Ballalai Ferraz A1, Rosim R1, Anaya P2
1IMS Health, São Paulo, Brazil, 2IMS Health, México, D.F., Mexico

RM2

17:45 - 18:00

EXTRACTING AND USING DATA FROM ELECTRONIC MEDICAL RECORDS (EMR) TO MONITOR QUALITY OF CARE AND PRESCRIPTION PATTERNS FOR DIABETES PREVENTION AND CONTROL IN OUTPATIENT CLINICS OF LOW AND MID RESOURCES COUNTRIES: THE CASE OF COLIMA, MEXICO

Hernández-Ávila JE1, Lara A2, Morales-Carmona E1, Espinoza EG2, Anaya P3, Palacio-Mejía LS1
1Instituto Nacional de Salud Pública, Cuernavaca, Mexico, 2Secretaría de Salud de Colima, Colima, Mexico, 3IMS Health, México, D.F., Mexico

RM3

18:00 - 18:15

COMPARISON OF SOCIAL EQ-5D TIME TRADE-OFF VALUES IN CHILE 2008-2013: DO GEOGRAPHICAL DIFFERENCES REALLY MATTER?

Zárate V1, Kind P2, Valenzuela P3
1Ministerio de Salud, Santiago, Chile, 2HSE University, St Petersburg, Russia, 3Datavoz, Santiago, Chile

RM4

18:15 - 18:30

MODELO DE CARACTERIZACIÓN DE UNA POBLACIÓN AFILIADA A UNA ASEGURADA EN COLOMBIA, MEDIANTE UNA METODOLOGÍA DE AGRUPACIÓN POR RIESGO

Romero M1, Marrugo Figueroa RD2, Benavides M3, Alzate P3, Reinales J4, Quinche G4, Barrios E4
1Salutia Foundation, Bogotá, Colombia, 2Fundación Salutia, Bogotá, Colombia, 3Salutia Foundation, Bogota, Colombia, 4Coomeva Group, Cali, Colombia
Contact ISPOR @ info@ispor.org | View Legal Disclaimer
© 2018 International Society for Pharmacoeconomics and Outcomes Research.
All rights reserved under International and Pan-American Copyright Conventions.